* If you want to update the article please login/register
Aerosol lung gene therapy using non-viral delivery technologies is a cost-effective treatment method for chronic respiratory diseases such as cystic fibrosis. Progress in a CF clinical setting using the lipidic formulation GL67A has shown the benefits of such a plan while emphasized the need for more potent gene transfer agents. In recent years, several new non-viral gene delivery systems have been developed as potential alternatives to GL67 cationic lipid. GL67A's comparative study was conducted with a clinically relevant administration protocol by aerosol in murine lungs in this study. Over half the animal's lifetime was found to mediate long-term lung transgene expression with just one of many formulations. This research clearly supports the promise of aminoglycoside-based cationic lipids as potent GL67-alternative scaffolds for further enhanced aerosol non-viral lung gene therapy for diseases such as CF.
Source link: https://doi.org/10.3390/pharmaceutics14010025
Cefepime liposomes with phosphatidylcholine and cholesterol contained a higher encapsulation-efficiency ratio in liposomes with phosphatidylcholine and cholesterol than with 1,2-dioleoyl-phosphoethanolamine, according to the study, which revealed a higher encapsulation-efficiency percentage of cefepime in liposomes with phosphatidylcholine and cholesterol than in 1,2-d The bactericidal activity against Escherichia coli of cefepime loaded into phosphatidylcholine liposomes was determined. In an agar plate for free cefepime, the inhibitory zone was similar to that used for loaded cefepime. E. coli culture's growth-rate constant was also determined in working conditions, as shown by work conditions. PC:CH:12NBr liposomes are biocompatible nanocarriers of cefepime that can be used in bacterial infections of Escherichia coli with high inhibitory activity, according to the researchers.
Source link: https://doi.org/10.3390/pharmaceutics11020069
DC-Chol liposomes had the highest immune response among a panel of cationic liposomes injected with influenza hemagglutininin, according to a previous research. In addition, we investigated the impact of the HA loading technique and the encapsulation of immune modulators in DC-Chol liposomes on HA's immunogenicity.
Source link: https://doi.org/10.3390/pharmaceutics5030392
Mucosal vaccine kits are considered a viable option to combat this issue. Here, we show that a host double-stranded DNA derived at the site of a cationic liposome injection plays an important role in the cationic liposome's mucosal adjuvanticity. Namely, we found that nasal administration of the cationic liposomes resulted in localized cell death at the site of injection, resulting in extracellular leakage of host dsDNA. In addition, cationic liposomes significantly reduced OVA-specific mucosal and systemic antibody production in vivo DNase I therapy.
Source link: https://doi.org/10.3390/vaccines8010008
Because of their ability to transfect cells with high accuracy, Cationic liposomes have been considered as potential gene delivery vectors for gene delivery. The combination of diagnostic agent and therapeutic agents in the same particle has been used to create a theranostic device for the first time since. Both types of magnetic liposomes improved their transverse and longitudinal relaxivities. r 2 and r 1 were obtained with both types of magnetic liposomes compared to free magnetic nanoparticles. Our MCLs, according to these results, may be a promising candidate for image-guided gene therapy.
Source link: https://doi.org/10.3390/pharmaceutics12090854
IRNA/2X3-DOPE complexes shielded L929 cells from encephalitis virus infection, according to in vitro results, while isRNA/P1500 complexes were not active, indicating lower transfection activity in cell culture. In vivo, a comparison of isRNA's interferon-inducing activity in BALB/c, CBA, and C57Bl/6 mice revealed that PEGylated liposomes significantly raise the interferon-inducing activity of isRNA. The delivery method had a major effect on the isRNA's antiviral activity in vivo. In vivo, the cationic liposomes 2X3-DOPE did not improve isRNA's antiviral characteristics, but not in vivo. The administration of isRNA in C57Bl/6 resulted in a decrease in virus titers in the lungs and a dramatic reduction in the severity of the infection. According to the data, isRNA in combination with the PEGylated delivery system could be a safe way to fight influenza A infection.
Source link: https://doi.org/10.3390/pharmaceutics12090875
We investigated the effects of cationic lipid type in folate -polyethylene glycol -modified cationic liposomes on gene-silencing in tumor cells using cationic liposomes/siRNA complexes in this research. In comparison, FA-PEG-modification of cationic liposomes in cationic liposomes restored gene-silencing activity, regardless of the cationic lipid type in cationic liposomes. However, among the three species of cationic liposomes, the optimal amount of PEG-lipid and FA-PEG-lipid in cationic liposomes for selective gene silencing and cell uptake was different. In vitro therapy, FA-PEG-modified liposomes demonstrated strong cytotoxicity in KB cells, as well as those of FA-PEG-modified PLK1 siRNA lipoplexes. The optimal formulation of PEG- and FA-modified liposomes for FR-selective gene silencing in vitro and in vivo transfection can be different between in vitro and in vivo transfection.
Source link: https://doi.org/10.3390/pharmaceutics11040181
Prostate cancer is the second most common cancer in men worldwide and the fifth leading cause of cancer deaths. In addition, because prostate cancer cells express Her2, an anti-Her2 targeting antibody will enhance the liposome's affinity for the cell and optimize intratumoral penetration of the ASO, thus increasing efficiency. Free ASO and ASO were tested in vitro using human PC-3 prostate cancer cells as a canonical model, while 2D and 3D spheroid models were tested for toxicity in vitro. We found significant differences in the efficacy of encapsulated ASO, which were always more effective than free ASO. ASO liposomes were more effective than ASO-immunoliposomes for short exposure times.
Source link: https://doi.org/10.3390/pharmaceutics12121166
Mice tested results showed that formulation F and parent formulation L had no acute and persistent toxic disease in mice, despite a comprehensive review of acute and chronic toxicity of this liposomal formulation in healthy C57BL/6J mice. The determination of tumor cells with different expression levels of folate receptors in SCID mice with xenograft tumors was strongly dependent on the deposition of folate receptors in tumor cells, but only in tumors that were isolated by cells with the highest FR levels. On a multidrug-resistant KB-8-5 tumor xenograft in SCID mice, siMDR1/F complexes and polychemotherapy has shown that siMDR/F promotes tumor growth, reduced necrosis, and inflammation, and increases apoptosis in KB-8-5 tumor tissue, according to researchers.
Source link: https://doi.org/10.3390/pharmaceutics13081252
To enhance the immunogenic characteristics, we tested two different DNA vaccines in cationic liposomes. For this, we cloned the coding sequences of the Plasmodium falciparum reticulocyte binding protein homologue 5 either alone or fused with very small HBsAg particles with PfRH5 on their outside, possibly resulting in HBsAg particles showing PfRH5 on their exterior. Mice were immunized with 10 bcg encapsulated DNA encoding PfRH5 alone or in combination with HBsAg, which produced antibodies against schizont extracts. According to PfRH5-HBs, only IgG-mediated inhibition in vitro growth assays showed continued IgG-mediated inhibition after 48 hours and 39 h, respectively. The encapsulated PfRH5-HBsAg coded DNA is safe and effective compared to unfused PfRH5-DNA vaccine, indicating that the HBsAg fusion may be more cost-effective and efficient with other vaccination antigens.
Source link: https://doi.org/10.3390/vaccines8040619
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions